Have Been Scheduled
COV - Upcoming Dividend Payouts
Next Ex-Dividend Date
|Amount||Declare Date||Ex-Dividend Date ▲||Record Date||Pay Date||Payout Type|
|No Upcoming Dividend Dates|
COV - Dividend Yield & Stock Price History
Current Dividend Yield
COV - Dividend Payout History
Current Annual Payout
Dividend.com DARS Rating™ Breakdown for COV
COV - Dividend Growth History
Last 5 Yrs
Last 3 Yrs
|Reveal Dividend Growth History for COV.||4.3%||-29.7%||5 years|
COV - Historical Annual Dividend Data & Growth
Payouts Increasing For
|Payout Amount||Calendar Year||Annual Growth|
COV - Historical Dividend Data
Payouts Increasing For
|Payout Amount||Declared Date||Ex-Dividend Date||Record Date||Pay Date ▼||Qualified Dividend?||Payout Type||Frequency|
Covidien (COV) - News
Today's Pre-Market Earnings: Moody's Corporation, Tyco International Ltd., Covidien plc, More (MCO, TYC, COV, More)Jul 25, 2014Before the opening bell on Friday, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these...
Over the weekend it was announced that American medical device maker Medtronic (MDT) has agreed to purchase Ireland-based medical device maker...
Today's Pre-Market Earnings: VF Corp, Whirlpool Corporation, Weyerhaeuser Company, More (VFC, WHR, WY, More)Apr 25, 2014Before Friday's opening bell, a number of big name, dividend paying companies announced their quarterly earnings. Below, we look at these earnings...
Covidien Boosts Dividend Payout by 23.1%; Now Offering a 2% Yield (COV)Sep 19, 2013Early on Thursday, healthcare product company Covidien plc (COV) announced that it is raising its quarterly dividend payout from 26 cents per share to 32 cents per share, a 23.1% increase. This next dividend will be paid on November 5 to shareholders of record on October 10, with an ex-dividend date of October 8. "This increase reflects our good performance to date in 2013 and our confidence in further growth," said Joe E. Almeida, Chairman, President and CEO of Covidien. "We remain committed to using our strong cash flow to fund business expansion, while returning at least 50% of our free cash flow to shareholders through dividends and share repurchases. In the last twelve months, we have exceeded this target, returning over 125% of our free cash flow to shareholders." "As we have previously announced, the Company intends to continue to increase its dividend and is targeting a dividend payout ratio -- dividends paid per share divided by adjusted earnings per share -- in excess of 35% over time," Almeida added. "Because of this, we expect dividends to increase at or above the rate of earnings growth for the next several years." Covidien shares were inactive during pre-market trading on Thursday. The stock is up 8.87% year-to-date.
Covidien Outlines Growth Strategies for 2014 (COV)Sep 12, 2013At a meeting held for the investing community on Thursday, Covidien (COV) went over its plans for 2014. The Bermuda-based healthcare company "outlined the key strategic initiatives, growth opportunities and innovations that are expected to drive the Company’s growth in 2014 and beyond," and provided updated guidance for its 2014 sales figures. Chairman, President and CEO José (Joe) E. Almeida had the following to say about the company's strategies for the coming year: "We are evolving our commercial model, offering value-added services, and launching a steady stream of new products in all product lines. Our strategic investment opportunities, combined with additional portfolio management activities, will accelerate our growth. We will use our strong cash flow to fund business expansion, while remaining committed to return at least 50% of our free cash flow to shareholders through dividends and share repurchases.” The company sees net sales for 2014 increasing 2% to 5% over sales from 2013. COV shares were down 52 cents, or .85%, at market close on Thursday. YTD, the company's stock is up more than 19.5%.
The Bottom LineShares of Covidien (COV) have a yield of 1.69% based on Thursday's closing price of $61.40 and the company's annualized payout of $1.04. Covidien (COV) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
Goldman Sachs analysts upgraded Covidien plc (COV) on Wednesday due to the healthcare products manufacturer's accelerating growth profile. The...
Needham & Co. Initiates Coverage of Covidien at "Buy" (COV)Sep 4, 2013Early on Wednesday, Needham & Co. analysts started coverage of Covidien plc (COV) with a bullish rating, as the medical supplies company has multiple growth drivers. The analysts rate COV as "Buy" and see shares reaching $69. This price target suggests a 16% upside to the stock's Tuesday closing price of $59.59. Needham & Co. analyst Mike Matson commented, "COV is a diverse medical supplies company with multiple growth drivers. Its operating margins are well below its peers and we see ample margin expansion opportunities. And COV's strong free cash flow should enhance investor returns through share repurchases and a dividend. Given this, and a valuation that is at a discount to peers, we are initiating coverage with a Buy rating." Covidien shares were inactive during pre-market trading on Wednesday. The stock is up 3.2% year-to-date. The Bottom Line Shares of Covidien (COV) offer a dividend yield of 1.75% based on Tuesday's closing price of $59.59 and the company's annualized dividend payout of $1.04 per share. Covidien plc (COV) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
Covidien Q2 Profits Drop; Beats Estimates (COV)Aug 1, 2013Healthcare product company Covidien plc (COV) posted lower third quarter profits on Thursday, as a result of higher expenses. The Ireland-based company's earnings for the third quarter came in at $396 million, or 84 cents per share, down from $453 million, or 93 cents per share in the third quarter of 2012. GAAP earnings from contining operations were $400 million, or 85 cents per share, up from last year's GAAP earnings of $395 million, or 81 cents per share. Excluding special items, earnings remained flat at 91 cents per share. Analysts expected to see earnings of 89 cents per share. Total revenue for the quarter rose to $2.58 billion from $2.51 billion a year ago. Revenue reported for the third quarter matched analysts estimate of $2.58 billion. Covidien's president and CEO Jose E Almeida noted, "operational sales growth was in line with our expectations, but our reported sales growth was restrained by the strength of the U.S. dollar against most foreign currencies." Covidien shares were up 88 cents, or 1.43%, during Thursday morning trading. The stock is up 7% YTD. The Bottom Line Shares of Covidien plc (COV) have a 1.69% yield, based on Wednesday's closing price of $61.63. Covidien plc (COV) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
BMO Capital Markets Cuts Price Target on Covidien (COV)Jun 28, 2013BMO Capital Markets reported on Friday that it has lowered its price target on healthcare product company, Covidien plc (COV) . The firm has maintained an "Outperform" rating on COV, but has cut the company's price target from $72 to $64. This price target suggests a 2% upside from the stock's current price of $62.86. An analyst from the firm noted, “Covidien management has provided a tremendous amount of detail to aid investors with their evaluations of ‘RemainCo' and Mallinckrodt as standalone businesses, and we believe the transaction is well understood. Now the focus will shift to execution, against FY2Q13 results which raised some questions, and FY2013 guidance, which we view as reasonable, if not somewhat conservative. This said, our investment thesis on COV remains: the company's diversified portfolio and global footprint should allow it to manage through changes in healthcare, drive operating margin expansion, and deliver revenue above the market growth rate, looking for mid-single-digits that could be leveraged to high-single-digits/low-double-digits over time.” Covidien shares were mostly flat during Friday morning trading. The stock is up 9% YTD. The Bottom Line Shares of Covidien plc (COV) have a 1.66% yield, based on Friday morning's price of $62.63. Covidien plc (COV) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.
Goldman Sachs Announces New Price Target On Covidien (COV)Jun 19, 2013Goldman Sachs announced on Wednesday that it is resuming coverage on Covidien (COV) after suspending its prior rating and price target following the Mallinckrodt spin-off. David Roman, an analyst with the firm, noted, "Based on the now standalone Medical Devices/Supplies entity, we are projecting sales and EPS of $10.296bn (+4.5% yoy) and $3.70 (+2.7% yoy) for FY13E, respectively. For FY14E, we are modeling $10.743bn (+4.3%) and $4.01 (+8.3%). As a reminder, Covidien's revenue growth profile will likely be pressured for the next 2-3 quarters given FX headwinds and tough comparisons in key businesses (Vascular). EPS growth should also be depressed through 1HFY14, driven by higher spending (investments in pipeline products and emerging markets), the medical device excise tax, and FX translation headwinds." Analysts at Goldman have a "Neutral" rating on this stock along with a price target of $64. Covidien shares sank sharply lower on Wednesday, shedding 3.59% on the day. The stock is up 10% YTD. The Bottom Line Shares of Covidien (COV) have a 1.58% yield, based on Wednesday's closing price of $63.57. Covidien (COV) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars. Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.